Background Intrahepatic cholangiocarcinoma (ICC) is the second most common primary
liver tumor. The resectability rate is low because at the time of diagnosis this disease is …

Modulating protein ubiquitination via proteasome inhibition represents a promising target
for cancer therapy, because of the higher sensitivity of cancer cells to the cytotoxic effects of …

Background and Aims Percutaneous radiofrequency ablation (RFA) demonstrated good results
for the treatment of hepatocellular carcinoma (HCC) in cirrhotic patients; it is still not clear …

The histological grade of carcinomas describes the ability of tumor cells to organize in
differentiated epithelial structures and has prognostic and therapeutic impact. Here, we show that …

The retrotransposon Long Interspersed Element 1 (LINE-1 or L1) is a continuing source of
germline and somatic mutagenesis in mammals. Deregulated L1 activity is a hallmark of …

Tumors driven by activation of the transcription factor MYC generally show oncogene
addiction. However, the gene expression programs that depend upon sustained MYC activity …

MYC is a key oncogenic driver in multiple tumor types, but concomitantly endows cancer
cells with a series of vulnerabilities that provide opportunities for targeted pharmacological …

The oncogenic transcription factor Myc is required for the progression and maintenance of
diverse tumors. This has led to the concept that Myc itself, Myc-activated gene products, or …

High-grade B cell lymphomas with concurrent activation of the MYC and BCL2 oncogenes,
also known as double-hit lymphomas (DHL), show dismal prognosis with current therapies. …

Deubiquitinating enzymes are key regulators of the ubiquitin-proteasome system and cell
cycle, and their dysfunction leads to tumorigenesis. Our in vivo drop-out screens in patient-…